Wednesday, March 13, 2024 10:36:50 PM
Sometimes, in cases like Owains, where barely any of the tumor was saved due to the emergency nature of the surgery, they are only able to make two or three doses. Not ideal, because many antigen targets might get skipped.
However, Upon recurrence, Owain now has plenty of tumor material from the new distal tumor. This means comprehensive and properly preserved tissue made into lysate likely carries enough Antigen bandwidth for DCVax-l to work better (hopefully in Owain’s case) and hopefully reduce the chance of tumor escape.
Dr. Bosch gave a different example of a patient dealing with recurrence. They fought and won. Stay hopeful.
Recent NWBO News
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
